Cayston superior to tobramycin in CF study

Gilead Sciences Inc. (NASDAQ:GILD) said Cayston aztreonam met the co-primary endpoint of superiority to inhaled tobramycin in the Phase III Study 205-0110 trial to treat pulmonary Pseudomonas aeruginosa infections in patients with cystic fibrosis (CF). The inhaled formulation of aztreonam was superior in mean change in percent predicted forced expiratory volume in one second (FEV1) across three treatment cycles over six months (2.05% increase vs. 0.66% decrease, p=0.0023). In June, Gilead reported that Cayston met the other co-primary endpoint, non-inferiority to inhaled tobramycin in mean percent change from baseline in percent predicted FEV1 at day 28 (8.35% vs. 0.55% increases, p=0.0001). ...